Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/49094
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2019-11-28T08:08:52Z-
dc.date.available2019-11-28T08:08:52Z-
dc.date.issued2015-06-
dc.identifier.citationWirth, F., Zahra, G., Xuereb, R. G., Barbara, C., Fenech, A., & Azzopardi, L. M. (2015, June). Pharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary intervention. Poster session presented at the Nordic Social Pharmacy and Health Services Research Conference & The Nordic Networking Group for Clinical Pharmacy, Tartu, Estonia.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/49094-
dc.description.abstractA poster presentation regarding pharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary intervention. Background: CYP2C19, a cytochrome P450 enzyme encoded by a highly polymorphic gene, is involved in the metabolism of clinically important drugs such as clopidogrel. The 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy, classify CYP2C19 genotypes into 4 groups according to metaboliser status in relation to clopidogrel: ‘Extensive metabolisers’, carrying only normal function alleles (EMs *1/*1), ‘ultra-rapid metabolisers’, carrying at least one gain-of-function (GoF) allele (UMs *1/*17, *17/*17), ‘intermediate metabolisers’, carrying one loss-of-function (LoF) allele (IMs *1/*2, *2/*17), and ‘poor metabolisers’, carrying two LoF alleles (PMs *2/*2). Objective: To implement a laboratory-based, pharmacist-led process to genotype patients who were prescribed clopidogrel therapy post-percutaneous coronary intervention (PCI) for the CYP2C19 LoF (*2) and GoF (*17) variant alleles.en_GB
dc.language.isoenen_GB
dc.publisherUniversity of Malta. Department of Pharmacyen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectClopidogrelen_GB
dc.subjectCoronary heart disease -- Chemotherapy -- Maltaen_GB
dc.subjectPharmacogenetics -- Maltaen_GB
dc.subjectCoronary arteries -- Stenosis -- Preventionen_GB
dc.titlePharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary interventionen_GB
dc.typepresentationen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedN/Aen_GB
dc.contributor.creatorWirth, Francesca-
dc.contributor.creatorZahra, Graziella-
dc.contributor.creatorXuereb, Robert G.-
dc.contributor.creatorBarbara, Christopher-
dc.contributor.creatorFenech, Albert-
dc.contributor.creatorAzzopardi, Lilian M.-
Appears in Collections:Scholarly Works - FacM&SPha



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.